Interactive Transcript
0:01
Okay, the next topic we're
0:02
going to review is T1 mapping.
0:04
T1 mapping is used for direct quantitative
0:06
measurement of the T1 time of tissues.
0:09
This is useful because your standard CMR sequences,
0:13
although you can put an ROI on a sequence and get
0:15
a signal intensity measurement, that measurement
0:18
is not standardized and does not actually
0:19
correlate to the real T1 time of the tissues.
0:22
So the nice thing about T1 mapping techniques
0:24
and also T2 mapping techniques that we'll
0:26
talk about later, are that you can actually
0:29
measure directly the T1 times
0:32
of the tissue in milliseconds.
0:34
Now, why is that useful?
0:35
T1 mapping may detect diffuse scar not
0:38
visualized on late gadolinium enhancement
0:40
images or abnormal sphingolipid deposition,
0:44
um, which is specific to Fabry's disease.
0:46
So the idea here is that your T1 can
0:49
be altered in the presence of fibrosis.
0:52
And what happens with fibrosis is
0:54
that you get replacement of myocytes
0:57
with fibrotic tissue and collagen.
0:59
That fibrotic tissue increases
1:02
the amount of extracellular fluid
1:04
in the heart muscle, and then that extracellular
1:07
fluid volume can actually be measured by T1 mapping
1:10
because the extra water content elongates the T1
1:13
time and results in basically an altered T1 map.
1:19
In the case of Fabry's disease, actually, you have
1:21
deposition because of the metabolic abnormality
1:23
associated with Fabry's disease you actually have
1:25
all these sphingolipids, which deposit
1:27
themselves within the cells themselves.
1:29
And those are primarily composed of fat.
1:32
And as we know, fat has a very short T1 time.
1:36
And so, um, with Fabry's disease
1:37
actually is really interesting.
1:38
You can see a shortened T1 time, uh,
1:41
due to all the sphingolipid deposition.
1:43
It's important to note here that T1
1:45
mapping is really used for diffuse processes.
1:49
So when you have, uh, what's called
1:51
interstitial or diffuse fibrosis,
1:53
you get collagen interspersed with myocytes.
1:56
Um, so these things don't really show
1:58
up on the late gadolinium enhancement images.
2:01
Late gadolinium enhancement is great for identifying
2:03
focal fibrosis, which means that basically all the
2:06
myocytes are dead and they've been replaced by scar.
2:09
That's where the gadolinium infiltrates,
2:11
and we see that on the post-contrast images.
2:13
With diffuse fibrosis though, because
2:16
it's a uniform process across the heart
2:18
and you have a mixture of
2:20
myocytes and interstitial fibrosis and collagen,
2:24
you're, you're not actually going to pick up
2:25
anything on the late gadolinium enhancement images.
2:28
So basically, the way this works, it's pretty simple,
2:31
is that the techniques are mapping the T1 recovery curve.
2:35
So you perform a 180-degree inversion of the spins,
2:39
and then you wait for that T1 recovery to happen and
2:42
sample the signal after the different inversion times.
2:45
So just basically wait at a whole bunch of
2:47
different points on the recovery curve and image.
2:49
And then if you map that out pixel-wise with
2:53
a graph, then you can extract the T1 time.
2:57
And, um, lastly, the T1 mapping can be performed
3:00
with two different approaches, either the TI
3:02
scout, which is our standard sequence that
3:05
we use to identify the correct inversion time for
3:07
the late gadolinium enhancement images or dedicated
3:11
sequences known as modified Look-Locker sequences,
3:15
MOLLI, or you may even see the term shMOLLI, which
3:18
is SH-MOLLI which means, um, basically shortened MOLLI,
3:21
uh, which is in pretty wide use today.
3:25
The only difference between these two
3:27
sequences—
3:28
they're both valid.
3:30
The problem with the TI scout is that it's not
3:32
normalized to cardiac motion, meaning that you're
3:34
going to get images all throughout the cardiac cycle.
3:37
Whereas the MOLLI is nice because each image
3:39
is in the same part of the cardiac cycle.
3:41
So you can, it's much easier to do a
3:44
segmentation and basically
3:47
measure the times across the multiple images.
3:52
So here's an example of using
3:54
Look-Locker for T1 mapping.
3:57
And in this case, you can see, actually,
3:59
it doesn't look like the myocardium position changes
4:02
much from phase to phase, which is surprising,
4:05
but generally, usually, you're going to see some.
4:08
This patient must have a very slow heart rate.
4:10
You'll usually see that the heart contracts, actually,
4:13
during the acquisition, which is what makes it a
4:15
little more difficult than the MOLLI technique.
4:17
Um, but what we get here is you,
4:19
you actually end up graphing the signal.
4:21
You do an ROI and you can either do a full
4:24
heart ROI, or maybe what's most often used is
4:26
just a, an oval-shaped ROI in the mid septum.
4:30
And then you graph those points across time.
4:33
So this is the intensity of that ROI, and this is
4:36
the time, the inversion time, and from that graph
4:39
can be extracted a best-fit line, and the best-fit
4:43
line there is basically defining the T1 recovery
4:46
curve, and from that curve, the program is able to
4:49
calculate a T1 time, and that's done on a pixel-by-
4:52
pixel basis when you actually create a T1 color map,
4:56
and then when you do an ROI, it actually takes an
4:58
average T1 time for the pixels included in that ROI.
5:02
The same process here is shown
5:04
with the MOLLI T1 mapping.
5:07
The difference here is that the
5:08
number of data points is much smaller.
5:10
You have just a few data points here
5:12
to calculate your T1 recovery curve, unlike
5:15
quite a few more data points on the Look-Locker.
5:18
But like I said, the advantage here is
5:20
that they're all from the same part of
5:21
diastole, so actually a little bit easier.
5:24
Okay, uh, just some notes about T1 mapping and
5:27
how they're expressed in the literature and how
5:29
one might describe them in clinical reports.
5:33
There are basically two different flavors
5:34
of values that you get from T1 mapping.
5:37
And there are different camps
5:39
out there in the research world.
5:41
And some people are really behind one technique
5:44
and other people are really behind others.
5:46
I don't necessarily have a strong opinion on this other
5:48
than the fact that I think the native T1, the first
5:51
technique is, is just easier.
5:53
So, um, my general bias is to try
5:56
and do, keep things fairly simple.
5:58
So I would tend to favor that
6:00
technique because of the ease of use.
6:01
But basically, um, the two different
6:04
techniques are native T1 and ECV.
6:05
Native T1, you'd perform a non-contrast
6:08
T1 map, and you measure the T1 time.
6:12
Generally, for looking for diffuse
6:13
disease, we do measurements of an
6:15
oval-shaped ROI within the mid septum.
6:18
ECV is extracellular volume, and this
6:22
is actually a measurement that uses
8:24
post-contrast and pre-contrast images.
6:27
It's expressed as a percentage, and that percentage,
6:30
what that percentage means is the percentage of
6:32
tissue that is composed of extracellular space.
6:35
So, in a certain given quantity of myocardial
6:38
tissue, the ECV is the percentage of that
6:41
myocardial tissue that is extracellular.
6:44
If you subtracted that from one,
6:46
the remainder would be the percentage of that
6:47
tissue that is cellular, meaning myocytes.
6:50
And so basically, if your tissue is composed
6:52
of a combination of myocytes and extracellular
6:55
space, the more fibrosis you get,
6:58
the relatively greater percentage of that
7:00
tissue is composed by extracellular space.
7:03
So increasing ECV percentage equals worsening fibrosis.
7:08
And the thing that makes this tricky is
7:10
that it's a map created from pre- and post-
7:13
contrast images and uses the—
7:16
basically, the difference of their T1 times
7:18
normalized to hematocrit to calculate this.
7:21
And so what is, what makes this complicated?
7:23
Well, one is now you're doubling any errors by using
7:26
two sets of images, a pre- and a post-set of T1.
7:30
Um, you're going to match those images.
7:32
So the patient has to be consistent in terms of
7:35
where their heartbeat and where you're acquiring
7:38
the images in diastole, and the patient, you know,
7:40
can't have moved in the bore of your scanner.
7:42
Um, and so that can present problems.
7:44
And then the hematocrit is another issue.
7:47
Hematocrit isn't necessarily
7:48
widely available for every patient.
7:50
So do you do an extra test of hematocrit the day of?
7:52
Is that necessary?
7:54
Generally, you like to have a hematocrit
7:55
that's fairly recent, within 24 hours.
7:58
It can fluctuate over time.
7:59
Um, so that, that creates another potential hurdle.
8:03
Okay.
8:04
So, uh, on this next slide, I'm going to
8:06
present exactly how ECV is calculated.
8:10
Basically, it's a subtraction technique
8:12
that's normalized to the hematocrit.
8:14
This is all happening on the backend.
8:16
So, you know, you don't have to do this
8:17
manually, but this is what's happening.
8:20
If you use any analysis software, generally, they're
8:22
going to ask you to contour the pre-contrast and
8:24
the post-contrast imaging, and then
8:27
provide a hematocrit, and this is what's happening
8:30
in the background on a pixel-by-pixel basis.
8:32
The T1 times of the myocardium
8:33
and the blood are being compared.
8:35
The T1 times of post-contrast are subtracted
8:38
from pre-contrast, and same with the blood,
8:41
and they're normalized to hematocrit.
8:42
And from that, you get an ECV number.
8:45
Here's just an example from the
8:46
literature of a case where they measured
8:49
the T1 time before and after contrast.
8:51
So you see that post-contrast, the T1 is
8:53
quite a bit shorter, 429 milliseconds versus 982.
8:57
And that's because of the GAD effects.
8:59
And so, you know, if you took the difference there,
9:00
you'd get, you know, 400 something in difference, and then
9:03
you'd normalize that to hematocrit, and divide it by the
9:05
blood pool, and so on, and you get your ECV number.
9:09
So this is actually my, uh,
9:10
first chance to show you guys this paper,
9:13
which came out in 2020, it’s super useful.
9:17
It's in the Journal of
9:19
Cardiovascular Magnetic Resonance.
9:21
What's fantastic about that is this is
9:23
an open-access journal, so anyone could
9:26
get it just by searching for it online.
9:28
It's called Reference Ranges or Normal
9:30
Values for Cardiovascular Magnetic
9:32
Resonance in Adults and Children.
9:33
There was an older version from several
9:35
years ago, and now it's been updated,
9:38
and it's almost like a book in a way.
9:40
I mean, it is an article, but it's an incredibly long
9:43
article because they've included so many different
9:46
normal ranges for any type of thing you're looking for.
9:49
So normal LV sizes, normal LA sizes, normal
9:53
aortic sizes, and so on and so forth.
9:56
So, inside of this really great reference.
9:59
You can get native T1 as well as ECV
10:01
ranges from a bunch of different publications.
10:05
And so, I'll just focus on the normal ranges
10:08
here as well as the standard deviation
10:10
and the upper and lower limits of normal.
10:12
And you see that for native T1 times, depending on
10:15
the technique, around the high 900s for 1.5 T,
10:20
and around the low thousands for 3 T.
10:23
Um, and so it's important to know that if
10:25
you are doing 3 T, the T1 time is longer.
10:28
And then ECV percentage somewhere
10:30
around that 25, 26 percent range.
10:32
So upper limits of normal hover around the 30% range or so.
10:38
So generally, the number we keep in mind if
10:40
we're doing ECV is around 30, whereas for the
10:42
native T1 times, it's somewhere around, you know,
10:45
1000 to 1100 or so in one and a half Tesla, and
10:50
over 1200 or 1300 or so for, for three Tesla.
10:54
Both native T1 and ECV have
10:57
been studied, as we talked about.
10:58
And, um, one note here, if you look at articles
11:01
out there, although we have these normal ranges,
11:03
it's important to note that the T1 is a bit
11:06
of a tricky — the N NT2, we'll talk about later,
11:09
it's a bit of a tricky sequence in that you
11:11
can compare to normals that are published,
11:14
but there's always a little bit of local variation.
11:16
And so all the guidelines out there would recommend
11:19
that you establish your local reference ranges.
11:21
How do you do that?
11:22
Well, they've suggested that one should
11:25
basically start paying attention to your
11:27
cases, get T1 in a whole bunch of cases.
11:30
If you can ideally find maybe about 20 cases that
11:34
are normal, you know, that let's say it's a rule
11:37
out sarcoidosis case and you don't find any cardiac
11:39
sarcoidosis, you can use that as a normal and then
11:42
use that to establish a local reference range.
11:46
Okay.
11:46
This is just a nice graph that if you ever go to
11:49
a talk about T1 mapping, you'll see this over and
11:52
over, and over again; it comes from this paper,
11:55
which is a guideline statement from the same
11:57
journal JCMR, which again is open access, so super
12:00
helpful, um, which is a consensus statement that
12:02
was put out in 2017 about how to use T1 and T2
12:06
mapping. This is the statement that I mentioned
12:08
that says you should really create your own
12:10
local references for what the normal values are.
12:13
And I just point this out because I think,
12:16
you know, oftentimes when we think about
12:17
T1, especially, there's some questions to,
12:20
you know, what should you really use it for?
12:22
What do the numbers mean?
12:24
My personal opinion is that the most important
12:27
diagnoses that are useful for T1 are Fabry's disease.
12:30
You can use it because if you have Fabry's
12:33
disease, you will see a really, really low T1
12:36
time that's quite a bit separated from normal.
12:39
And then the other one is amyloidosis.
12:41
So amyloidosis, the T1 times here, very,
12:46
very different from normal, very elongated
12:49
in the case of native T1 values
12:51
and very elevated in the case of ECV.
12:54
So in my opinion, um, these two diagnoses
12:57
have the best separation from normal patients.
13:01
Um, whereas although these look
13:03
on this graph that they're well separated
13:07
from normal patients in sort of real
13:08
world clinical experience, these diagnoses—
13:11
so HCM, dilated cardiomyopathy, etc.—
13:14
there's really so much overlap with normal
13:16
patients, it's really difficult to make much
13:18
sense of what that means. So the use of the
13:21
T1 number to define, you know, the extent of
13:24
diffuse fibrosis, and so on, is a little more difficult
13:27
in these sort of more chronic diseases that aren't
13:30
so significantly different from normals.